Natco in pact with US firm for two ANDA

Natco Pharma has signed a letter of intent (LoI) with the USA based Akorn Inc, to develop and supply two abbreviated new drug application (ANDA) oral tablet drugs for cancer patients suffering from nausea and vomiting.

According to a release issued by Natco Pharma to the BSE today, the company will be responsible for the development and manufacturing of both the drugs, while Akorn will be responsible for marketing and distribution in the US and Canada healthcare markets.

"The two ANDA drug products will focus on the anti-emetic market, and have a current market size of approximately $ 800 million," the release added.